Hormone Replacement Therapy

Prevention or alleviation of moderate to severe menopausal signs and symptoms such as vasomotor effects, depressive mood changes, vaginal dryness, urogenital atrophy, osteoporosis, cardiovascular disease, and cognitive dysfunction

Treatment of physiologic and physical manifestations of primary ovarian insufficiency

Increased risk of VTE due to increased generation of fibrin, reduction in plasma levels of protein S, resistance to activated protein C, and higher levels of C-reactive proteins

May cause reduction in fibrinogen, decrease in level of plasminogen activator inhibitor-I, leading to enhancement of fibrinolytic potential and prolonged bleeding

Increased risk of VTE including DVT, PE, stroke, and MI with HRT

Increased risk of fibrinolysis and prolonged bleeding with combination estrogen-progestin